GlassScriptPhysician profile
Elizabeth A Baxter
NPI 1760551550
$4,480.10
in general payments reported to CMS, 2019-2025
29 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $581 · 2021: $842 · 2022: $722 · 2023: $865 · 2024: $347 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.48 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $465.29 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $398.45 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $374.65 | 2019-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $341.87 | 2019-2024 | Trintellix |
| Allergan, INC. | $323.55 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $273.69 | 2019-2024 | Ingrezza |
| Lundbeck LLC | $243.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $218.14 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $190.61 | 2022-2025 | Auvelity |
| Alkermes, INC. | $176.82 | 2022-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.00 | 2020-2024 | Caplyta |
| Jazz Pharmaceuticals INC. | $133.32 | 2019-2022 | |
| Eisai INC. | $101.90 | 2020-2021 | |
| Bausch Health US, LLC | $94.21 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $81.33 | 2019-2020 | |
| Neos Therapeutics, LP | $61.92 | 2020-2022 | |
| Livanova USA, INC. | $57.45 | 2022-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Supernus Pharmaceuticals, INC. | $48.27 | 2022 | |
| Noven Therapeutics, LLC | $46.44 | 2021-2024 | Xelstrym, Secuado |
| Shire North American Group INC | $40.49 | 2019 | |
| Tris Pharma INC | $35.88 | 2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $35.50 | 2020-2021 | |
| Corium, LLC | $21.87 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.56 | 2020 | |
| Noven Pharmaceuticals, INC. | $17.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.14 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $14.11 | 2019 | |
| Merck Sharp & Dohme LLC | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.